about
Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuriaCost-effectiveness of the School-Based Asthma Therapy (SBAT) programEconomic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada.Probabilistic sensitivity analysis in health economics.Cost-effectiveness of telehealth for patients with depression: evidence from the Healthlines randomised controlled trial.Comparing multiple competing interventions in the absence of randomized trials using clinical risk-benefit analysisFlexible parametric joint modelling of longitudinal and survival data.Cost-effectiveness of a computerized provider order entry system in improving medication safety ambulatory care.Data and interpretation: economic evaluations in transfusion medicine, Part 4.Methods to construct a step-by-step beginner's guide to decision analytic cost-effectiveness modeling.Implantable loop recorders are cost-effective when used to investigate transient loss of consciousness which is either suspected to be arrhythmic or remains unexplained.Improving patient adherence to lifestyle advice (IMPALA): a cluster-randomised controlled trial on the implementation of a nurse-led intervention for cardiovascular risk management in primary care (protocol).Handling uncertainty in economic evaluations of patient level data: a review of the use of Bayesian methods to inform health technology assessments.Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuityA pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer.Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study.Comparison of complementary and alternative medicine with conventional mind-body therapies for chronic back pain: protocol for the Mind-body Approaches to Pain (MAP) randomized controlled trial.The effect of mindfulness training prior to total joint arthroplasty on post-operative pain and physical function: study protocol for a randomised controlled trial.Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United KingdomCost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom.An epidemiologic model to project the impact of changes in glomerular filtration rate on quality of life and survival among persons with chronic kidney disease.Cost modeling of preoperative axillary ultrasound and fine-needle aspiration to guide surgery for invasive breast cancer.Estimating the costs of induced abortion in Uganda: a model-based analysis.Depression in working adults: comparing the costs and health outcomes of working when ill.Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities.Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study.Potential cost-effectiveness of universal access to modern contraceptives in Uganda.Systems of support to increase colorectal cancer screening and follow-up rates (SOS): design, challenges, and baseline characteristics of trial participantsThe economic effect of extracorporeal membrane oxygenation to support adults with severe respiratory failure in Brazil: a hypothetical analysis.The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application.Cost-utility analysis of nt-probnp-guided multidisciplinary care in chronic heart failure.The clinical decision analysis using decision treeThe cost-effectiveness of expanded testing for primary HIV infection.Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in CanadaPredicting health utilities for children with autism spectrum disorders.Towards a comprehensive simulation model of malaria epidemiology and control.Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis.Evaluating the effects of increasing physical activity to optimize rehabilitation outcomes in hospitalized older adults (MOVE Trial): study protocol for a randomized controlled trialThe impact of the HEART risk score in the early assessment of patients with acute chest pain: design of a stepped wedge, cluster randomised trial
P2860
Q28175859-8EE0CA10-C05A-4118-AC77-34D0C4EAB73BQ28243221-1E9FE90D-7B2D-46D7-8BFF-CFE0F9D4DC29Q28394885-6522B656-FCB7-4949-B7BE-5AE048A78895Q30278856-55681C40-6B3F-40F7-A348-B45078E34C2BQ30407247-E1F634E2-133C-41C8-9719-348C09C0058EQ30490118-56F510EF-88DF-4C3A-8DE4-1CC24464A10BQ30506096-179A50C7-22C5-43BA-9007-A1A356E89D44Q30572063-EACCE0BF-CC73-4552-AA8A-B49E711EDA41Q30582516-91DCB37A-249D-4156-B167-3A72AA84CCDFQ30612788-C0470C47-DBAE-441E-BC12-128D17712794Q30823226-B992D77E-83D4-401A-88EC-C03F5E0355CCQ33160650-71CF7DC1-2E91-43F6-95E0-A0E070A88EF9Q33314627-F51F2998-F816-4E45-A16A-D17A6E85B55FQ33511681-8DF492A6-DBB6-46A0-9DAD-C367BAB713FAQ33633742-4446DEA1-9998-49D1-81FA-DB33365A706FQ33646171-DA4EA567-13BB-43B0-9991-11571DC10282Q33709566-D6C9C921-6353-4C1B-8D4E-D9A0AE5C11A3Q33736626-08AC8404-FA4C-457E-9A1B-5C89604604F9Q33760977-32AECFB0-B506-4C78-B3FC-CC0C1501C560Q33821666-2F778E77-456C-4416-9403-E0DB240AA603Q33850011-4B2998E8-5632-4D3D-9A37-92D1952E962DQ33862914-D2475D07-5BF0-4E12-BF50-E2E0255F35E2Q34011844-7A4F6F58-7A59-4FEC-9BF7-D7750F82E56BQ34092751-BF922831-7731-4CEF-AB51-9EF28027B636Q34122051-61D8AF8F-DB56-40CA-BB28-920F01D65A2DQ34141636-A6928554-4A25-423B-8DC5-87C146F2FAF2Q34147730-B962EBEB-6204-4687-B02A-5599FF97194AQ34170209-C68629BC-350F-4025-A866-18E75DC1D217Q34209451-59767878-4A29-41B7-8A6B-F999331B6247Q34301034-C7464552-0D8B-43D7-AA63-580269AE4AFFQ34513206-C4843053-2762-44D0-800A-653CCFD7DBBEQ34519372-6736C0E7-F020-4D03-8F47-E958DC393FF4Q34608270-4A626EFF-7BDA-4F6E-BCAA-0DDEAB31AA03Q34629478-1306395E-8724-4523-B592-C201D72B5D81Q34637866-AE281F13-C40C-4B2F-92A3-9637AA114B39Q34735353-9A5BB34D-FE97-48EA-9F9A-74CD09682922Q34806993-7A6F2FA7-83F9-464F-84CF-D1B0C7F6E474Q34857094-24EF7C7B-2761-4EBC-9FBC-B9B92FE708ECQ34998773-E099883F-4CB1-4EA3-B51F-ED5847EBF587Q34999971-D72B5DB0-4B2A-405B-93E7-A4FBC423F08A
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Handling uncertainty in cost-effectiveness models.
@ast
Handling uncertainty in cost-effectiveness models.
@en
Handling uncertainty in cost-effectiveness models.
@nl
type
label
Handling uncertainty in cost-effectiveness models.
@ast
Handling uncertainty in cost-effectiveness models.
@en
Handling uncertainty in cost-effectiveness models.
@nl
prefLabel
Handling uncertainty in cost-effectiveness models.
@ast
Handling uncertainty in cost-effectiveness models.
@en
Handling uncertainty in cost-effectiveness models.
@nl
P1433
P1476
Handling uncertainty in cost-effectiveness models.
@en
P2093
P2860
P304
P356
10.2165/00019053-200017050-00006
P577
2000-05-01T00:00:00Z
P6179
1036413222